GlassScriptPhysician profile
Fadi N Chaaban
NPI 1316947906
$160,943.17
in general payments reported to CMS, 2019-2025
48 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $16K · 2021: $16K · 2022: $20K · 2023: $22K · 2024: $29K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $6,589 · Consulting Fee: $4,800 · Travel and Lodging: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,990.00 |
| Food and Beverage | $6,588.78 |
| Consulting Fee | $4,800.00 |
| Travel and Lodging | $923.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69,480.45 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68,033.86 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $9,912.21 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $4,959.26 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,260.17 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,066.36 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $756.00 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $748.77 | 2019-2025 | |
| Boston Scientific Corporation | $694.68 | 2019-2025 | Watchman Flx, Watchman |
| Astrazeneca Pharmaceuticals LP | $459.18 | 2019-2025 | Farxiga |
| Heartflow, INC. | $322.51 | 2023-2025 | Ffrct |
| Vifor Pharma, INC. | $245.14 | 2019-2023 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $233.95 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $233.47 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $229.16 | 2021-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $190.48 | 2022-2025 | Cardiomems, Aveir, Mitraclip |
| Amarin Pharma, INC. | $176.29 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $133.33 | 2021 | |
| Edwards Lifesciences Corporation | $129.85 | 2022 | |
| Scpharmaceuticals INC. | $128.65 | 2023-2025 | |
| Medtronic Vascular, INC. | $125.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $112.31 | 2022 | |
| Esperion Therapeutics, INC. | $111.21 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $103.76 | 2019-2024 | |
| Shockwave Medical, INC | $100.00 | 2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Philips North America LLC | $89.07 | 2022-2025 | (Ck4) Mcot, Extended Holter |
| Kowa Pharmaceuticals America, INC. | $82.12 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $79.18 | 2023-2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $72.78 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $69.86 | 2022-2025 | Amvuttra |
| Arbor Pharmaceuticals, INC. | $60.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $60.35 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $57.00 | 2025 | Attruby |
| Atricure, INC. | $55.23 | 2025 | Atriclip Laa Exclusion System |
| Irhythm Technologies, INC. | $53.15 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Davol INC. | $47.03 | 2019 | |
| Baxter Healthcare | $36.43 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Ionis Pharmaceuticals, INC. | $35.80 | 2025 | Tryngolza |
| Itamar Medical INC | $34.78 | 2022 | |
| Inari Medical, INC. | $25.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Altathera Pharmaceuticals LLC | $23.67 | 2024 | Sotalol Hydrochloride |
| Amryt Pharma Holdings LTD | $19.18 | 2020 | |
| Cleerly, INC. | $19.08 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Glaxosmithkline, LLC. | $18.23 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $15.93 | 2024 | Arcalyst |
| Lundbeck LLC | $15.00 | 2020 | |
| Sun Pharmaceutical Industries INC. | $14.40 | 2021 | |
| Welch Allyn | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Chaaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.